Comparative Pharmacology
Head-to-head clinical analysis: ALBUTEROL SULFATE IPRATROPIUM BROMIDE versus DETROL LA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBUTEROL SULFATE IPRATROPIUM BROMIDE versus DETROL LA.
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE vs DETROL LA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albuterol sulfate is a beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle. Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors, reducing bronchoconstriction and mucus secretion.
Tolterodine is a competitive muscarinic receptor antagonist. It blocks acetylcholine binding at muscarinic receptors (M1–M5), reducing detrusor muscle contraction and bladder pressure, thereby increasing bladder capacity and decreasing urinary frequency.
2 inhalations (each inhalation delivers 90 mcg albuterol sulfate and 18 mcg ipratropium bromide) four times daily via oral inhalation; maximum 12 inhalations in 24 hours.
4 mg orally once daily; may be reduced to 2 mg once daily based on tolerability.
None Documented
None Documented
Albuterol: terminal half-life 3.8-6 hours; Ipratropium: terminal half-life 1.5-4 hours (clinical: twice-daily dosing for chronic therapy).
Terminal elimination half-life is approximately 7 hours (range 5-10 hours) for the extended-release formulation, allowing once-daily dosing.
Albuterol: renal excretion of unchanged drug and metabolites (~60-70% as metabolites, ~10-20% unchanged); Ipratropium: primarily renal (~50% unchanged), with biliary/fecal excretion accounting for minor amounts.
Approximately 77% eliminated in urine (primarily as metabolites, <1% unchanged) and 17% in feces.
Category A/B
Category C
Anticholinergic
Anticholinergic